Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
用户1vmuUF1gAVhM
4天前
70
10
已完结
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-12-04 11:08:47 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
请帮忙下载这个文章的所有补充材料，谢谢！
SA Harrison, MR Bashir, CD Guy, R Zhou, CA Moylan…
The Lancet, 2019
thelancet.com
… -approved treatments exist. The results of our phase 2 study show the efficacy of resmetirom … of inflammation and fibrosis and non-alcoholic steatohepatitis with fibrosis on liver biopsy at …
